Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

James Manning

Orthopaedic Surgery Las Vegas, NV Medical Doctor

NPI 1871588996 CMS profile 85437

2680 Crimson Canyon Dr, Las Vegas, NV 89128

Open in the dashboard

General payments

$6,161

60 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, James Manning of Las Vegas, NV is reported in the CMS Open Payments database as having received $6,161 across 60 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 60th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $422 5
2024 General $1,728 16
2023 General $405 3
2022 General $1,521 20
2021 General $236 3
2020 General $149 5
2019 General $1,700 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Manning
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to James Manning were reported at $422. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year James Manning Orthopaedic Surgery median Middle half National median
2019 $1,700 $644 $140–$2,844 $163
2020 $149 $312 $75–$1,860 $114
2021 $236 $520 $117–$2,495 $132
2022 $1,521 $598 $128–$2,731 $149
2023 $405 $461 $128–$2,264 $160
2024 $1,728 $497 $134–$2,475 $164
2025 $422 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Goode Surgical Inc $2,861 18 payments
  2. Arthrex, Inc. $2,264 25 payments
  3. Smith+Nephew, Inc. $444 8 payments
  4. Embody, Inc. $189 1 payment
  5. Stryker Corporation $152 2 payments
  6. Flexion Therapeutics, Inc. $138 1 payment
  7. Nevro Corp. $34 1 payment
  8. SI-BONE, Inc. $30 1 payment
  9. Zimmer Biomet Holdings, Inc. $19 1 payment
  10. Ethicon US, LLC $16 1 payment
  11. Other $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $2,554 7 payments
  2. Food and Beverage $2,329 52 payments
  3. Education $1,279 1 payment
Products named General payments · program years 2019–2025
  1. TAPESTRY $189 1 payment
  2. JOURNEY II $145 1 payment
  3. Zilretta $138 1 payment
  4. MAKO $134 1 payment
  5. REGENETEN Shoulder $86 2 payments
  6. Bioinductive Implant with Arthroscopic Delivery System - Medium $71 1 payment
  7. Bone Anchors with Arthroscopic Delivery System $68 1 payment
  8. HEALICOIL $68 1 payment
  9. NOVOSTITCH $51 2 payments
  10. Fast-Fix 360 $35 1 payment
  11. Other $189 9 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

91

Median for Orthopedic Surgery: 203

Drug cost

$1,057

Median for Orthopedic Surgery: $1,433

Branded share of claims

25.3%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 21 $628
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 23 $216
Ibuprofen Generic 19 $162
Prednisone Generic 28 $52

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$69,163

Of which drugs: $7,246

Medicare patients

221

Average age 76

Services billed

6,223

129 women, 92 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 33%
Diabetes 29%
Chronic kidney disease 27%
Atrial fibrillation 21%
Cancer 18%
Depression 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg J7325 Office 13 928 $6,493
Injection, methylprednisolone acetate, 1 mg J1010 Office 77 4,362 $434
Injection, methylprednisolone acetate, 80 mg J1040 Office 35 42 $246
Injection, methylprednisolone acetate, 40 mg J1030 Office 21 23 $73

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

60 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record